{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T22:31:18Z","timestamp":1795213878790,"version":"4.10.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The burden of carbapenem resistance is not well studied in the Middle East. We aimed to describe the molecular epidemiology and outcome of carbapenem-resistant Enterobacterales (CRE) infections from several Saudi Arabian Centers.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a multicenter prospective cohort study conducted over a 28-month period. Patients older than 14\u00a0years of age with a positive CRE <jats:italic>Escherichia coli<\/jats:italic> or <jats:italic>Klebsiella pneumoniae<\/jats:italic> culture and a clinically established infection were included in this study. Univariate and multivariable logistic models were constructed to assess the relationship between the outcome of 30-day all-cause mortality and possible continuous and categorical predictor variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 189 patients were included. The median patient age was 62.8\u00a0years and 54.0% were male. The most common CRE infections were nosocomial pneumonia (23.8%) and complicated urinary tract infection (23.8%) and 77 patients (40.7%) had CRE bacteremia. OXA-48 was the most prevalent gene (69.3%). While 100 patients (52.9%) had a clinical cure, 57 patients (30.2%) had died within 30\u00a0days and 23 patients (12.2%) relapsed. Univariate analysis to predict 30-day mortality revealed that the following variables are associated with mortality: older age, high Charlson comorbidity index, increased Pitt bacteremia score, nosocomial pneumonia, CRE bacteremia and diabetes mellitus. In multivariable analysis, CRE bacteremia remained as an independent predictor of 30\u00a0day all-cause mortality [AOR and 95% CI\u2009=\u20092.81(1.26\u20136.24), p\u2009=\u20090.01].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These data highlight the molecular epidemiology and outcomes of CRE infection in Saudi Arabia and will inform future studies to address preventive and management interventions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07507-y","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T08:03:08Z","timestamp":1655107388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia"],"prefix":"10.1186","volume":"22","author":[{"given":"Basem M.","family":"Alraddadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L. G.","family":"Heaphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamama","family":"Aljishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Eljaaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan H.","family":"Al-Turkistani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer N.","family":"Alshukairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed O.","family":"Qutub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kholoud","family":"Alodini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roaa","family":"Alosaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalya","family":"Attalah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakan","family":"Alswaiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed F.","family":"Saeedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Al-Hamzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama K.","family":"Hefni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem S.","family":"Almaghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushira","family":"Anani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhakeem","family":"Althaqafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"4","key":"7507_CR1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","volume":"8","author":"D van Duin","year":"2017","unstructured":"van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460\u20139.","journal-title":"Virulence"},{"issue":"2","key":"7507_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","volume":"75","author":"D van Duin","year":"2013","unstructured":"van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115\u201320.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"7507_CR3","unstructured":"WHO: 2017."},{"issue":"7","key":"7507_CR4","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3201\/eid2007.121004","volume":"20","author":"ME Falagas","year":"2014","unstructured":"Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20(7):1170\u20135.","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"7507_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1086\/592412","volume":"29","author":"G Patel","year":"2008","unstructured":"Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099\u2013106.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"7507_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1128\/CMR.05035-11","volume":"25","author":"LS Tzouvelekis","year":"2012","unstructured":"Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682\u2013707.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"7507_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154092","volume":"11","author":"MV Villegas","year":"2016","unstructured":"Villegas MV, Pallares CJ, Escand\u00f3n-Vargas K, Hern\u00e1ndez-G\u00f3mez C, Correa A, \u00c1lvarez C, Rosso F, Matta L, Luna C, Zurita J, et al. Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing Enterobacteriaceae in seven Latin American Countries. PLoS ONE. 2016;11(4): e0154092.","journal-title":"PLoS ONE"},{"issue":"6","key":"7507_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1473-3099(18)30792-8","volume":"19","author":"AJ Stewardson","year":"2019","unstructured":"Stewardson AJ, Marimuthu K, Sengupta S, Allignol A, El-Bouseary M, Carvalho MJ, Hassan B, Delgado-Ramirez MA, Arora A, Bagga R, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis. 2019;19(6):601\u201310.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"7507_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1469-0691.2011.03478.x","volume":"18","author":"D Ben-David","year":"2012","unstructured":"Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18(1):54\u201360.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"7507_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jiph.2019.03.024","volume":"12","author":"F Alotaibi","year":"2019","unstructured":"Alotaibi F. Carbapenem-Resistant Enterobacteriaceae: an update narrative review from Saudi Arabia. J Infect Public Health. 2019;12(4):465\u201371.","journal-title":"J Infect Public Health"},{"issue":"12","key":"7507_CR11","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1016\/S1473-3099(18)30414-6","volume":"18","author":"RA Moghnieh","year":"2018","unstructured":"Moghnieh RA, Kanafani ZA, Tabaja HZ, Sharara SL, Awad LS, Kanj SS. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect Dis. 2018;18(12):e379\u201394.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"7507_CR12","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/AAC.00782-08","volume":"53","author":"GL Daikos","year":"2009","unstructured":"Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, Skoutelis A, Georgousi K, Tzouvelekis LS, Tassios PT, Bamia C, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53(5):1868\u201373.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"7507_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","volume":"17","author":"B Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Pa\u00f1o-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cant\u00f3n R, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726\u201334.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"7507_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1186\/s12879-019-4409-1","volume":"19","author":"BM Alraddadi","year":"2019","unstructured":"Alraddadi BM, Saeedi M, Qutub M, Alshukairi A, Hassanien A, Wali G. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infect Dis. 2019;19(1):772.","journal-title":"BMC Infect Dis"},{"key":"7507_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2021.05.079","volume":"109","author":"HA Hakeam","year":"2021","unstructured":"Hakeam HA, Alsahli H, Albabtain L, Alassaf S, Al Duhailib Z, Althawadi S. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis. 2021;109:1\u20137.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"7507_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin infect Dis. 2018;66(2):163\u201371.","journal-title":"Clin infect Dis"},{"key":"7507_CR17","doi-asserted-by":"crossref","unstructured":"Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jim\u00e9nez-Mart\u00edn MJ et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017; 61(2).","DOI":"10.1128\/AAC.01964-16"},{"issue":"3","key":"7507_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/jpids\/piz002","volume":"8","author":"PD Tamma","year":"2019","unstructured":"Tamma PD, Hsu AJ. Defining the role of novel \u03b2-lactam agents that target carbapenem-resistant gram-negative organisms. J Pediatric Infect Dis Soc. 2019;8(3):251\u201360.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"7507_CR19","doi-asserted-by":"publisher","first-page":"ofab026","DOI":"10.1093\/ofid\/ofab026","volume":"8","author":"K Eljaaly","year":"2021","unstructured":"Eljaaly K, Bidell MR, Gandhi RG, Alshehri S, Enani MA, Al-Jedai A, Lee TC. Colistin nephrotoxicity: meta-analysis of randomized controlled trials. Open Forum Infect Dis. 2021;8(2):ofab026.","journal-title":"Open Forum Infect Dis"},{"key":"7507_CR20","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline."},{"issue":"1","key":"7507_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagac\u00e9-Wiens PRS, Walkty A, Denisuik A, Golden A, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations. Drugs. 2018;78(1):65\u201398.","journal-title":"Drugs"},{"issue":"9","key":"7507_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00698-21","volume":"65","author":"L Chen","year":"2021","unstructured":"Chen L, Han X, Li Y, Li M. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Enterobacterales. Antimicrob Agents Chemother. 2021;65(9): e0069821.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"7507_CR23","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/j.1469-0691.2011.03514.x","volume":"17","author":"O Zarkotou","year":"2011","unstructured":"Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798\u2013803.","journal-title":"Clin Microbiol Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07507-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T08:04:06Z","timestamp":1655107446000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07507-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7507"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07507-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"15 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board of King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia (IRB #2018-57). We confirm that all methods were carried out in accordance with relevant guidelines and regulations of Helsinki declaration. The informed consent was waived by the Research Ethics Committee of King Faisal Specialist Hospital and Research Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"542"}}